Abstract
Prostate cancer is among the most common cancers in men worldwide. Despite treatment options, patients with metastatic disease have a five-year survival rate of only 29%, so development of new therapeutic strategies is needed in order to achieve long-term benefits. Treatment resistance mechanisms such as tumor heterogeneity and an immunosuppressive microenvironment prevent the establishme…